West Tower Group’s Cymabay Therapeutics CBAY Stock Holding History

West Tower Group’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,515	Closed	-$82.2K	–	806
2023 Q3	$82.2K	Buy	+5,515	New	+$73.1K	0.04%	121

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

West Tower Group's CBAY Position: Q4 2023 in Review

West Tower Group sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 5,515 shares — an estimated $82.2K sold.

West Tower Group first reported a position in CBAY in Q3 2023 and held it in 1 quarter. The position peaked at $82.2K in Q3 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

West Tower Group reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
West Tower Group sold 5,515 Cymabay Therapeutics shares in Q4 2023, an estimated $82.2K.
West Tower Group first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 1 quarter.
West Tower Group's Cymabay Therapeutics position peaked at $82.2K in Q3 2023.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on West Tower Group's 13F filing for Q4 2023, filed 14 Feb 2024.